Deals this week: Cantabio Pharma, Lupin, Shanghai Fosun Pharma, Intellia Therapeutics

14th April 2016 (Last Updated April 14th, 2016 18:30)

Cantabio Pharma has signed a drug discovery agreement with NovAliX S.A.S for the development of a new therapy for treatment of Alzheimer’s disease.

Novartis Healthcare

Cantabio Pharma has signed a drug discovery agreement with NovAliX S.A.S for the development of a new therapy for treatment of Alzheimer's disease.

The agreement enables the companies to develop small molecule chaperons that are known to stabilise abeta peptide, a process that is believed to potentially treat Alzheimer's disease.

Lupin and Novartis Healthcare have reached a co-marketing agreement to promote the latter's Loftair inhaler, which is a treatment for chronic obstructive pulmonary disease (COPD).

The agreement will pave way for commercialising Loftair in India. While Novartis will continue to market the product under its brand name Sequadra, Lupin will be responsible to promote Loftair.

The new product addition is expected to help Lupin improve its market in COPD, anti-asthma and inhalation therapies in its home country, India.

Shanghai Fosun Pharma plans to raise $928m from qualified investors in order to replenish its working capital and repay existing loans, including principal and interest.

Funding will be raised through private placement of renewable corporate bonds.

Intellia Therapeutics has announced to issue the shares of its common stock in an initial public offering (IPO) to raise gross proceeds of up to $120m.

The US-based biotechnology company has filed the registration statement for the planned IPO with the relevant authorities.

"Shanghai Fosun Pharma plans to raise $928m from qualified investors."

The proceeds will be invested partly in developing sentinel treatments, with the aim of submitting one IND. They will also be used to advance its in-vivo and ex-vivo pipeline products, delivery technologies and CRISPR/Cas9 gene editing platform, as well as for general corporate purposes.

Altor BioScience and National Cancer Institute (NCI) have signed cooperative research and development agreement for advancing the development of the former's cancer immunotherapy candidates ALT-803 and ALT-801.

The compounds are targeted for treatment of hematologic and solid tumour cancers.

ALT-803 is an interleukin-15 (IL-15) superagonist, whereas ALT-801 is a single-chain T-cell-receptor/Interleukin-2 (IL-2) fusion protein. Both the drugs are currently in Phase I and Phase II clinical trials.

EUSA Pharma has acquired global rights to rebrand Arcoral Pharma's oncology supportive care treatment Arcoral Tab as Caphosol.
The rights acquisition enables EUSA to improve the sales of its Caphosol product and also strengthen the portfolio of its oncology drugs and oncology supportive care.

Arcoral Tab is a topical oral agent approved for the treatment of certain conditions resulting in reduced salivary flow.


Image: Lupin and Novartis Healthcare have entered into a co-marketing agreement:Photo:courtesy of Novartis AG.